242 related articles for article (PubMed ID: 21798853)
1. (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells.
Choudhury SR; Balasubramanian S; Chew YC; Han B; Marquez VE; Eckert RL
Carcinogenesis; 2011 Oct; 32(10):1525-32. PubMed ID: 21798853
[TBL] [Abstract][Full Text] [Related]
2. The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival.
Balasubramanian S; Adhikary G; Eckert RL
Carcinogenesis; 2010 Mar; 31(3):496-503. PubMed ID: 20015867
[TBL] [Abstract][Full Text] [Related]
3. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
[TBL] [Abstract][Full Text] [Related]
4. The Bmi-1 helix-turn and ring finger domains are required for Bmi-1 antagonism of (-) epigallocatechin-3-gallate suppression of skin cancer cell survival.
Balasubramanian S; Scharadin TM; Han B; Xu W; Eckert RL
Cell Signal; 2015 Jul; 27(7):1336-44. PubMed ID: 25843776
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
6. Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
Kemp CD; Rao M; Xi S; Inchauste S; Mani H; Fetsch P; Filie A; Zhang M; Hong JA; Walker RL; Zhu YJ; Ripley RT; Mathur A; Liu F; Yang M; Meltzer PA; Marquez VE; De Rienzo A; Bueno R; Schrump DS
Clin Cancer Res; 2012 Jan; 18(1):77-90. PubMed ID: 22028491
[TBL] [Abstract][Full Text] [Related]
7. PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteins.
Zoabi M; Sadeh R; de Bie P; Marquez VE; Ciechanover A
Biochem Biophys Res Commun; 2011 May; 408(3):393-8. PubMed ID: 21513699
[TBL] [Abstract][Full Text] [Related]
8. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
[TBL] [Abstract][Full Text] [Related]
9. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells.
Du J; Li L; Ou Z; Kong C; Zhang Y; Dong Z; Zhu S; Jiang H; Shao Z; Huang B; Lu J
Breast Cancer Res Treat; 2012 Jan; 131(1):65-73. PubMed ID: 21465172
[TBL] [Abstract][Full Text] [Related]
10. The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors.
Bommi PV; Dimri M; Sahasrabuddhe AA; Khandekar J; Dimri GP
Cell Cycle; 2010 Jul; 9(13):2663-73. PubMed ID: 20543557
[TBL] [Abstract][Full Text] [Related]
11. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K
Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665
[TBL] [Abstract][Full Text] [Related]
12. Sulforaphane suppresses polycomb group protein level via a proteasome-dependent mechanism in skin cancer cells.
Balasubramanian S; Chew YC; Eckert RL
Mol Pharmacol; 2011 Nov; 80(5):870-8. PubMed ID: 21807989
[TBL] [Abstract][Full Text] [Related]
13. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.
Miranda TB; Cortez CC; Yoo CB; Liang G; Abe M; Kelly TK; Marquez VE; Jones PA
Mol Cancer Ther; 2009 Jun; 8(6):1579-88. PubMed ID: 19509260
[TBL] [Abstract][Full Text] [Related]
14. DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells.
Lee JK; Kim KC
Biochem Biophys Res Commun; 2013 Sep; 438(4):647-52. PubMed ID: 23933322
[TBL] [Abstract][Full Text] [Related]
15. (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells.
Nandakumar V; Vaid M; Katiyar SK
Carcinogenesis; 2011 Apr; 32(4):537-44. PubMed ID: 21209038
[TBL] [Abstract][Full Text] [Related]
16. Green tea-induced epigenetic reactivation of tissue inhibitor of matrix metalloproteinase-3 suppresses prostate cancer progression through histone-modifying enzymes.
Deb G; Shankar E; Thakur VS; Ponsky LE; Bodner DR; Fu P; Gupta S
Mol Carcinog; 2019 Jul; 58(7):1194-1207. PubMed ID: 30854739
[TBL] [Abstract][Full Text] [Related]
17. Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1.
Hernández-Muñoz I; Taghavi P; Kuijl C; Neefjes J; van Lohuizen M
Mol Cell Biol; 2005 Dec; 25(24):11047-58. PubMed ID: 16314526
[TBL] [Abstract][Full Text] [Related]
18. Role of histone H3 lysine 27 methylation in Polycomb-group silencing.
Cao R; Wang L; Wang H; Xia L; Erdjument-Bromage H; Tempst P; Jones RS; Zhang Y
Science; 2002 Nov; 298(5595):1039-43. PubMed ID: 12351676
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.
Sasaki D; Imaizumi Y; Hasegawa H; Osaka A; Tsukasaki K; Choi YL; Mano H; Marquez VE; Hayashi T; Yanagihara K; Moriwaki Y; Miyazaki Y; Kamihira S; Yamada Y
Haematologica; 2011 May; 96(5):712-9. PubMed ID: 21228036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
